Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 USDMF

2 API Suppliers
2 USDMF

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

DIGITAL CONTENT

8 NEWS #PharmaBuzz

media
8 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 209783-80-2, Ms-275, Sndx-275, Entinostat (ms-275), Ms 275, Ms-27-275

Molecular Formula

C₂₁H₂₀N₄O₃

Molecular Weight

376.4 g/mol

InChI Key

INVTYAOGFAGBOE-UHFFFAOYSA-N

FDA UNII

1ZNY4FKK9H

Entinostat is a synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.

1 2D Structure

Entinostat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate

2.1.2 InChI

InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)

2.1.3 InChI Key

INVTYAOGFAGBOE-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

2.2 Other Identifiers

2.2.1 UNII

1ZNY4FKK9H

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Ms 27-275

2. Ms 275

3. Ms-27-275

4. Ms-275

5. N-(2-aminophenyl)-4-(n-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide

6. Sndx-275

2.3.2 Depositor-Supplied Synonyms

1. 209783-80-2

2. Ms-275

3. Sndx-275

4. Entinostat (ms-275)

5. Ms 275

6. Ms-27-275

7. Sndx 275

8. Pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate

9. Ms 27-275

10. Ms275

11. Entinostat (ms-275,sndx-275)

12. 1zny4fkk9h

13. Bay 86-5274

14. N-(2-aminophenyl)-4-(n-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide

15. Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate

16. Chembl27759

17. Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate

18. Nsc706995

19. Bay86-5274

20. Nsc-706995

21. Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate

22. Ms-275-27

23. Carbamic Acid, N-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- Pyridinylmethyl Ester

24. Carbamic Acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl Ester

25. Pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate.

26. Pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate

27. N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic Acid 3-pyridinylmethyl Ester

28. Entinostatum

29. N-(2-aminophenyl)-4-[n-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide

30. Entinostat, Free Base

31. Entinostat [inn]

32. Entinostat [jan]

33. Entinostat [usan:inn]

34. Unii-1zny4fkk9h

35. Entinostat [usan]

36. Ms-275 - Entinostat

37. 3-pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate

38. Benzamide-type Inhibitor, 3

39. Carbamic Acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl Ester

40. Entinostat [who-dd]

41. Mls006010183

42. Entinostat (jan/usan/inn)

43. Schembl148309

44. Gtpl7007

45. Dtxsid0041068

46. Bdbm19410

47. Ex-a038

48. Chebi:132082

49. Bcpp000155

50. Hms3426g07

51. Hms3648k12

52. Hms3654o11

53. Hms3744o17

54. Act06782

55. Amy31163

56. Bcp01824

57. Zinc1488870

58. Mfcd08272435

59. Nsc756642

60. S1053

61. Entinostat (ms-275;sndx-275)

62. 3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate

63. Akos024262667

64. N-(2-aminophenyl)-4-[n-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide

65. Ac-8968

66. Bcp9000967

67. Carbamic Acid, 3-pyridinylmethyl Ester

68. Ccg-208680

69. Cs-0511

70. Db11841

71. Entinostat (ms-275, Sndx-275)

72. Nsc 706995

73. Nsc-756642

74. Sb16665

75. Carbamic Acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl Ester

76. Ncgc00165833-01

77. Ncgc00165833-02

78. Ncgc00165833-03

79. Ncgc00165833-04

80. Ncgc00165833-11

81. Ncgc00165833-13

82. 442532-99-2

83. As-17906

84. Bp-25653

85. Hy-12163

86. Nci60_038022

87. Smr004458705

88. Ms-275, A Hdac1 And Hdac3 Inhibitor

89. Zk 244894

90. E1454

91. Ft-0667871

92. Sw219667-1

93. Ec-000.2117

94. D09338

95. 783m802

96. A815057

97. Ms-275,entinostat, Sndx-275, Ms-27-275

98. Sr-01000946382

99. Q1281020

100. Sr-01000946382-1

101. W-201831

102. Brd-k77908580-001-02-1

103. Brd-k77908580-001-04-7

104. (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate

105. Pyridin-3-ylmethyl4-((2-aminophenyl)carbamoyl)benzylcarbamate

106. N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl Ester, Carbamic Acid

107. N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamic Acid 3-pyridinylmethyl Ester

108. Pyridin-3-ylmethyl ((4-((2-aminophenyl)carbamoyl)phenyl)methyl)carbamate

109. Sndx 275;3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₀N₄O₃
Molecular Weight	376.4 g/mol
XLogP3	2
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	376.15354051 g/mol
Monoisotopic Mass	376.15354051 g/mol
Topological Polar Surface Area	106 Å²
Heavy Atom Count	28
Formal Charge	0
Complexity	508
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Histone Deacetylase Inhibitors

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. (See all compounds classified as Histone Deacetylase Inhibitors.)

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

4.2 ATC Code

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01X - Other antineoplastic agents

L01XH - Histone deacetylase (hdac) inhibitors

L01XH05 - Entinostat

API SUPPLIERS